ES2752039T3 - Agente terapéutico para la dislipidemia - Google Patents

Agente terapéutico para la dislipidemia Download PDF

Info

Publication number
ES2752039T3
ES2752039T3 ES13842381T ES13842381T ES2752039T3 ES 2752039 T3 ES2752039 T3 ES 2752039T3 ES 13842381 T ES13842381 T ES 13842381T ES 13842381 T ES13842381 T ES 13842381T ES 2752039 T3 ES2752039 T3 ES 2752039T3
Authority
ES
Spain
Prior art keywords
group
compound
ezetimibe
salt
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13842381T
Other languages
English (en)
Spanish (es)
Inventor
Toshiaki Takizawa
Yasunobu Yoshinaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Application granted granted Critical
Publication of ES2752039T3 publication Critical patent/ES2752039T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13842381T 2012-09-27 2013-09-27 Agente terapéutico para la dislipidemia Active ES2752039T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27
PCT/JP2013/005756 WO2014050134A1 (ja) 2012-09-27 2013-09-27 脂質異常症治療剤

Publications (1)

Publication Number Publication Date
ES2752039T3 true ES2752039T3 (es) 2020-04-02

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13842381T Active ES2752039T3 (es) 2012-09-27 2013-09-27 Agente terapéutico para la dislipidemia

Country Status (20)

Country Link
US (4) US9572798B2 (https=)
EP (1) EP2902025B1 (https=)
JP (1) JP6238460B2 (https=)
KR (1) KR102098032B1 (https=)
CN (1) CN104640544B (https=)
AU (1) AU2013321918B2 (https=)
BR (1) BR112015006305B1 (https=)
CA (1) CA2901650C (https=)
EA (1) EA024873B1 (https=)
ES (1) ES2752039T3 (https=)
IL (1) IL237981B (https=)
IN (1) IN2015DN02966A (https=)
MX (1) MX357446B (https=)
MY (1) MY177686A (https=)
PH (1) PH12015500471A1 (https=)
PL (1) PL2902025T3 (https=)
PT (1) PT2902025T (https=)
SG (1) SG11201501740XA (https=)
TW (1) TWI598098B (https=)
WO (1) WO2014050134A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
US11419854B2 (en) 2017-06-30 2022-08-23 Kowa Company, Ltd. Medicament containing pemafibrate
JP7007379B2 (ja) * 2017-06-30 2022-02-10 興和株式会社 医薬組成物
US11298340B2 (en) * 2017-06-30 2022-04-12 Kowa Company, Ltd. Pharmaceutical composition
US11759456B2 (en) 2017-06-30 2023-09-19 Kowa Company, Ltd. Pharmaceutical composition
WO2019004447A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
JP7402687B2 (ja) * 2017-06-30 2023-12-21 興和株式会社 医薬組成物
HRP20241476T1 (hr) * 2017-06-30 2025-01-03 Kowa Company, Ltd. Farmaceutski pripravak
WO2019004453A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬品
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
JP2020105174A (ja) * 2018-12-27 2020-07-09 興和株式会社 医薬組成物
TWI891619B (zh) * 2018-12-27 2025-08-01 日商興和股份有限公司 醫藥品
US20220096443A1 (en) * 2018-12-27 2022-03-31 Kowa Company, Ltd. Pharmaceutical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7205321B2 (en) 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
JPWO2005009942A1 (ja) 2003-07-28 2006-09-07 杏林製薬株式会社 光学活性置換フェニルプロピオン酸誘導体
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
JP2008513458A (ja) 2004-09-16 2008-05-01 メルク エンド カムパニー インコーポレーテッド 異常脂質血症及び他の脂質障害の治療用化合物
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
AU2013321918B2 (en) 2018-05-10
HK1206620A1 (zh) 2016-01-15
EA024873B1 (ru) 2016-10-31
PL2902025T3 (pl) 2020-03-31
MY177686A (en) 2020-09-23
JP6238460B2 (ja) 2017-11-29
MX357446B (es) 2018-07-10
WO2014050134A1 (ja) 2014-04-03
TW201417811A (zh) 2014-05-16
EP2902025A1 (en) 2015-08-05
BR112015006305B1 (pt) 2020-11-17
CA2901650C (en) 2021-05-04
AU2013321918A1 (en) 2015-04-23
US20170112811A1 (en) 2017-04-27
EP2902025B1 (en) 2019-08-07
IL237981A0 (en) 2015-05-31
US11013722B2 (en) 2021-05-25
CN104640544B (zh) 2017-05-03
PT2902025T (pt) 2019-11-04
KR102098032B1 (ko) 2020-04-07
US20150196538A1 (en) 2015-07-16
EA201590653A1 (ru) 2015-07-30
CA2901650A1 (en) 2014-04-03
PH12015500471B1 (en) 2015-04-20
EP2902025A4 (en) 2016-03-02
TWI598098B (zh) 2017-09-11
PH12015500471A1 (en) 2015-04-20
MX2015003705A (es) 2015-06-10
SG11201501740XA (en) 2015-04-29
US20180185337A1 (en) 2018-07-05
IN2015DN02966A (https=) 2015-09-18
CN104640544A (zh) 2015-05-20
BR112015006305A2 (pt) 2017-07-04
US20190167645A1 (en) 2019-06-06
IL237981B (en) 2020-05-31
US9572798B2 (en) 2017-02-21
JPWO2014050134A1 (ja) 2016-08-22
US9931321B2 (en) 2018-04-03
KR20150063035A (ko) 2015-06-08
US10258609B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
ES2752039T3 (es) Agente terapéutico para la dislipidemia
JP6761346B2 (ja) 脂質異常症治療剤
US20200246314A1 (en) Dyslipidemia therapeutic agent
JP2018197273A (ja) 脂質異常症治療剤
WO2022224962A1 (ja) 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬
HK1206620B (en) Therapeutic agent for dyslipidemia
HK1237263A1 (en) Dyslipidemia therapeutic agent